Citations

Clear

4847 citation(s) found for "Yu, Eric".

Influence of acute graded hypoxia on the bronchial circulation in healthy humans
Ceridon, Maile L., Snyder, Eric M., Olson, Thomas P. , Hulsebus, Minelle L., Johnson, Bruce D.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.1150.15 Get It

Reduced partial pressures of inspired O 2 may influence the bronchial circulation through a number of mechanisms (e.g. altered pulmonary and systemic vascular pressures, lung fluid regulation, airway cooling & drying from increased ventilation). The present study examined the impact of acute, graded hypoxia on bronchial blood flow (Q aw ) in eight healthy adults (28 ± 9 years). Subjects were exposed to inspired O 2 levels resulting in arterial O 2 saturation (SaO 2 ) values of 90% and 80% for 15 min each. To control for the mild hyperventilation that accompanies hypoxia, subjects then mimicked the 80% SaO 2 ventilation (V E ) rate with 21% FIO 2 and again with CO 2 added to the inspirate to maintain normocapnia. Q aw and cardiac output (CO) were measured using soluble gas techniques. Also measured were alveolar‐capillary conductance (D m , index of lung fluid balance), pulmonary capillary blood volume (V c ), and systemic mean (MAP) and pulmonary arterial pressures (PAP). Hypoxia resulted in minimal change in MAP, a small rise in PAP, minimal change in CO and V c , and a rise in D m . There was also a non significant decrease in Q aw with hypoxia. Mild hyperventilation resulted in a significant fall in Q aw , but when normocapnia was maintained, Q aw returned to baseline values. These data suggest that acute, graded hypoxic exposure does not significantly impact Q aw , however, the hypocapnia associated with mild hyperventilation reduces Q aw .
Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database
Jin, Zhaohui , Dixon, Jesse G. , Fiskum, Jack, Yothers, Greg , Allegra, Carmen J. , Haller, Daniel G. , Gramont, Aimery de , Taı̈eb, Julien , Tweleves, Christopher, Sadahiro, Sotaro , Blanke, Charles D. , Tomita, Naohiro , Seitz, Jean‐François, Erlichman, Charles , Yamanaka, Takeharu , Goldberg, Richard M. , George, Thomas J. , Fiskum, Jack M, Yothers, Greg , Haller, Daniel , Kerr, Rachel , Taieb, Julien , Twelves, Christopher , O'Connell, Michael, Saltz, Leonard , Marsoni, Silvia , André, Thierry , Mahipal, Amit , Goldberg, Richard M , George, Thomas J , Shi, Qian , Jin, Zhaohui , Dixon, Jesse G , Parekh, Hiral D. , Sinicrope, Frank A. , Wolmark, Norman , Schmoll, Hans‐Joachim , Kerr, Rachel , Cutsem, Eric Van , Twelves, Chris , O’Connell, Michael J. , Saltz, Leonard B. , Yoshino, Takayuki , Marsoni, Silvia , André, Thierry , Mahipal, Amit , Shi, Qian

Mayo Clinic

JNCI: Journal of the National Cancer Institute | June 21, 2021 | Volume: 113 | Issue: 12 | Pages: 1693-1704

10.1093/jnci/djab123 | PMID 34405233 Get It

Abstract Background Colon cancer (CC) incidence in young adults (age 20-49 years), termed early-onset CC (EO-CC), is increasing. Methods Individual patient data on 35 713 subjects with stage III colon cancer from 25 randomized studies in the Adjuvant Colon Cancer ENdpoint database were pooled. The distributions of demographics, clinicopathological features, biomarker status, and outcome data were summarized by age group. Overall survival, disease-free survival, time to recurrence, and survival after recurrence were assessed by Kaplan-Meier curves and Cox models stratified by treatment arms within studies, adjusting for sex, race, body mass index, performance status, disease stage, grade, risk group, number of lymph nodes examined, disease sidedness, and molecular markers. All statistical tests were 2-sided. Results Using a 5% difference between age groups as the clinically meaningful cutoff, patients with stage III EO-CC had similar sex, race, performance status, risk group, tumor sidedness, and T stage compared with patients with late-onset CC (age 50 years and older). EO-CC patients were less likely to be overweight (30.2% vs 36.2%) and more commonly had 12 or more lymph nodes resected (69.5% vs 58.7%). EO-CC tumors were more frequently mismatch repair deficient (16.4% vs 11.5%) and less likely to have BRAFV600E (5.6% vs 14.0%), suggesting a higher rate of Lynch syndrome in EO-CC. Patients with EO-CC had statistically significantly better overall survival (hazard ratio [HR] = 0.81, 95% confidence interval [CI] = 0.74 to 0.89; P < .001), disease-free survival (HR = 0.91, 95% CI = 0.84 to 0.98; P = .01), and survival after recurrence (HR = 0.88, 95% CI = 0.80 to 0.97; P = .008) in the analysis without molecular markers; however, age at onset of CC lost its prognostic value when outcome was adjusted for molecular markers. Conclusion Tumor biology was found to be a more important prognostic factor than age of onset among stage III colon cancer patients in the Adjuvant Colon Cancer ENdpoint database.
Gene‐by‐Gene Interactions Between Phenylethanolamine N‐Methyltransferase and the Beta‐2 Adrenergic Receptor and the Ventricular Response to Exercise
Snyder, Eric M., Ji, Yuan , Weinshilboum, Richard M. , Johnson, Bruce D., Joyner, Michael J. , Turner, Stephen T. , Weinshilboum, Richard M.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.966.1 Get It

Epinephrine is a sympathomimetic which is derived from phenylalanine and tyrosine. The final step of epinephrine synthesis, the conversion from norepinephrine, relies on phenylethanolamine N‐methyltransferase (PNMT). The beta‐2 adrenergic receptor (ADRB2) binds to epinephrine and has several common functional polymorphisms including a Glycine (Gly) for Arginine (Arg) substitution at amino acid 16. We assessed the effect of the gene‐to‐gene interaction of these proteins on the ventricular response to exercise in healthy humans (n=69, age=29±6yrs, ht=174±10cm, wt=71±13kg). We found that within the 2*1 haplotype of the 5′FR, which has previously demonstrated greater epinephrine synthesis compared to 2*7 haplotype, the Arg16 genotype demonstrates lower stroke volume (SV) than the Gly16 genotype despite similar epinephrine levels and synthesis rates (Arg16= 75±5, Gly16=89±6ml/beat). Similarly, within the 2*7 haplotype of the 5′FR, which has demonstrated attenuated epinephrine synthesis compared to 2*1, the Arg16 genotype demonstrates a smaller SV than the Gly16 genotype (Arg16= 59±3, Gly16=78±6ml/beat). Additionally, the Arg16 and Gly16 subjects within the 2*1 haplotype of PNMT have greater stroke volume than their ADRB2 counterparts of the 2*7 haplotype of PNMT. These data demonstrate an interaction between the genes that encode PNMT and ADRB2 on the ventricular response to exercise.
EBF restricts alternate lineage options and promotes B cell fate commitment independently of Pax5
Lancki, D W, Pongubala, Jagan M.R. , Medina, Kay L. , Treiber, Thomas, Bertolino, Eric, Thomas, Matthew , Northrup, Daniel L. , Grosschedl, Rudolf , Allman, David A. , Singh, Harinder

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.844.4 Get It

Alternate lineage restriction and B cell fate commitment require the transcription factor Pax5, but the functions of EBF, in these processes remain largely unexplored. In the absence of EBF, expandable and clonal lymphoid progenitors retain considerable myeloid potential. Conversely, ectopic expression of EBF in multipotential progenitors directs B cell generation at the expense of myeloid cell fates. EBF induces Pax5 and antagonizes expression of C/EBPα , PU.1 and Id2 . Importantly, sustained expression of EBF in Pax5 −/− hematopoietic progenitors is sufficient to block their myeloid and T lineage potentials in vivo . Furthermore, in Pax5 −/− pro‐B cells increased EBF expression represses alternate lineage genes. Thus, EBF can restrict alternate lineage choice and promote B cell fate commitment independently of Pax5.
Arg16/Gly β 2 ‐adrenergic receptor polymorphism and forearm blood flow following dietary sodium restriction
Eisenach, John H., Pike, Tasha L., Johnson, Christopher P., Schrage, William G. , Snyder, Eric M., Johnson, Bruce D., Schroeder, Darrell R. , Johnson, Christopher P, Turner, Stephen T. , Joyner, Michael J.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 20 | Issue: 4 | Pages: No page available

10.1096/fasebj.20.4.a309-b Get It

The Gly allele of the Arg16/Gly β 2 ‐adrenergic receptor polymorphism has been associated with hypertension in a linkage analysis in Rochester, MN. Gly homozygotes have greater forearm β 2 ‐receptor mediated vasodilation than Arg after a normal Na + diet (150 mmol/day), and the difference is mediated by endothelial NO. To test the hypothesis that dietary Na + restriction affects β 2 ‐mediated dilation in these groups, we measured forearm blood flow (FBF, plethysmography) during brachial arterial infusion of isoproterenol (ISO) after 5 days of low dietary Na + (10 mmol/day), in healthy subjects homozygous for Arg (n=15, 8 women, 29 ± 8 yrs, mean ± SD) vs. Gly (n=17, 7 women, 31 ± 7 yrs). Baseline FBF did not differ between groups. ISO caused a significant increase in FBF that was not different based on genotype (P = 0.51, main effect of genotype; P = 0.72, genotype‐by‐ISO‐interaction). For example, the highest response to ISO was 10.3 ± 5.5 in Arg and 12.0 ± 4.4 ml/100 ml forearm vol/min in Gly (P t‐test = 0.33). NO inhibition with L‐NMMA decreased baseline FBF, and significantly blunted the response to ISO, but there was no evidence to suggest the responses were influenced by genotype (P = 0.89, genotype‐by‐ISO‐by‐L‐NMMA interaction). We conclude that greater NO‐mediated β 2 ‐receptor vasodilation in Gly homozygotes is no longer apparent following dietary Na + restriction, suggesting that greater dilator function in Gly homozygotes during normal Na + intake may be a protective vascular mechanism in a population where the Gly allele is associated with hypertension. Support: HL‐63328, GCRC RR‐00585, NCRR K23‐17520.
Repeat Length Polymorphism of the Serotonin Transporter Gene Influences Pulmonary Artery Pressure in Heart Failure
Olson, Thomas P. , Snyder, Eric M., Robert, Robert P, Johnson, Bruce D., Turner, Stephen T.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 20 | Issue: 4 | Pages: No page available

10.1096/fasebj.20.4.a403 Get It

Pulmonary hypertension is common in patients with heart failure (HF); however, for a given degree of left ventricular dysfunction, the range in pulmonary artery pressures (PAP) is large. Polymorphisms of a number of candidate genes have been implicated in contributing to smooth muscle dysfunction and remodeling of the pulmonary vasculature, including the serotonin transporter (5HTT) gene. Patients with HF may have mild tissue hypoxia, which may alter expression of 5HTT. This study examined the influence of a repeat length polymorphism in the promoter region of the 5HTT gene on differences in PAP in HF patients. Ninety HF patients (age=55±14yrs; LVEF=28±10%; NYHA=2.0±0.9) and 90 age and gender matched controls (CTL, age=51±15yrs; LVEF=63±7%) were recruited. Heart failure and CTL subjects were divided into 3 genotype groups, SS‐homozygotes for the short variant, LL‐homozygotes for the long variant and LS‐heterozygous condition. For both HF and CTL, SS n=20; LS n=41; LL n=29). PAP was calculated from the tricuspid regurgitant velocity. Age and gender did not differ between HF and CTL or among genotype groups. PAP was higher in HF compared to CTL (38.9±12.5 vs 27.7±8.2 mmHg, p<0.01, respectively) with a significant genotype effect in HF (SS=34.2±8.6 vs LS=38.2±11.4 vs LL=43.2±15.2 mmHg, p<0.05), but not in CTL. The HF group also demonstrated elevated left atrial diameter compared to CTL (HF 48.0±8.7 vs 32.8±4.8 mm, p<0.01, respectively) although no difference was seen within the HF group across genotypes. These results suggest that the LL variant of 5HTT is associated with elevated PAP in HF but not CTL. HL71478 and HL07111.
Abstract 127: Differences in Care Patterns, Health Status, and Outcomes of Atrial Fibrillation in Patients With and Without Diabetes: Findings From the ORBIT-AF Registry
Shrader, Peter, Thomas, Laine , Kowey, Peter R. , Singer, Daniel E. , Go, Alan S. , Piccini, Jonathan P. , Echouffo-Tcheugui, Justin B , Gersh, Bernard J. , Mahaffey, Kenneth W. , Hylek, Elaine M. , Peterson, Eric D. , Fonarow, Gregg C.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 21, 2021 | Volume: 10 | Issue: suppl_3 | Pages: No page available

10.1161/circoutcomes.10.suppl_3.127 Get It

Objective: Diabetes is a common among patients with atrial fibrillation (AF). However, little is known on the impact of diabetes on symptoms, health status, care and outcomes among AF patients. We assessed whether symptoms, health status, care and outcomes differ between AF patients with and without diabetes. Methods: This observational cohort study included 9,749 patients with AF from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation registry, a prospective, nationwide, multicenter outpatient registry of patients with incident and prevalent AF enrolled at 174 sites between June 2010 and August 2011. The outcomes were symptoms, health status, and AF treatment, as well as 2-year risks of death, readmission, thrombomebolic events, heart failure (HF) and AF progression. Results: Among AF patients; those with diabetes (29.5%) were younger and more likely to have hypertension, chronic kidney disease, HF, coronary heart disease, and stroke. Patients with diabetes had a lower Atrial Fibrillation Effects on Quality of Life score (80.6 [IQR: 62.5 - 92.6] vs. 82.4 [IQR: 67.6 -93.5]; P = 0.025), but a higher CHA 2 DS 2 -VASc score (5 [IQR: 4 - 6] vs. 4 [2 - 5]; P <0.0001) and were more likely to receive anticoagulation ( P <0.001). Diabetes was associated with higher mortality, with a greater overall (adjusted hazard ratio [aHR]: 1.63 [95% CI: 1.04-2.56] for age<70 vs. 1.25 [1.09-1.44] for age ≥70) and cardiovascular (2.20 [1.22-3.98] for age<70 vs. 1.24 [1.02-1.51] for age ≥70) mortality risks before age 70 years. Diabetes conferred a higher risk of non-cardiovascular (CV) death (1.29 [1.06-1.56]), sudden cardiac death (1.53 [1.04-2.26]), hospitalization (1.15 [1.09-1.22]), CV hospitalization (1.13 [1.05-1.22]) and non-CV and non-bleeding-related hospitalization (1.19 [1.10-1.30]); but no increase in risks of thromboembolic events, bleeding related hospitalization, new-onset HF, and AF progression. The use of oral anticoagulants (OAC) modifies the relation of diabetes and all-cause hospitalization, with a higher risk among those on OAC (1.21 [1.12-1.29]). Conclusions: Among patients with AF, diabetes was associated with worse AF symptoms and lower quality of life, as well an increased risk of death and hospitalizations, but not with the risk of thromboembolic or bleeding events.
Abstract 057: Understanding of Treatment Strategies Among Patients Newly Diagnosed With Atrial Fibrillation: Findings From SATELITTE
Kim, Sunghee , Pieper, Karen S. , Ezekowitz, Michael D. , Ansell, Jack , Berger, Peter B. , Reiffel, James A. , Singer, Daniel E. , Kowey, Peter R. , Piccini, Jonathan P. , O’Brien, Emily C. , Kaufman, Brystana G. , Fonarow, Gregg C. , Naccarelli, Gerald V. , Mahaffey, Kenneth W. , Chan, Paul S. , Allen, Larry A. , Freeman, James V. , Gersh, Bernard J. , Peterson, Eric D.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 21, 2021 | Volume: 10 | Issue: suppl_3 | Pages: No page available

10.1161/circoutcomes.10.suppl_3.057 Get It

Introduction: Patient understanding of available therapies for atrial fibrillation (AF) is foundational to shared medical decision making and long term medication adherence. Yet, there is a paucity of data regarding the extent to which patients newly diagnosed with AF in routine community practice understand their options. Hypotheses: 1) Understanding of warfarin, novel oral anticoagulants (NOAC), rhythm control therapy, cardioversion and radio frequency ablation changes little from baseline to 6 months and 2) treatment rates at 6 months are associated with patient understanding of therapies at baseline. Methods: We analyzed survey data from SATELLITE, a substudy of new-onset AF patients enrolled at 56 US sites participating in the ORBIT-AF registry. Patients were surveyed at the baseline and 6 month follow up clinic visit using Likert scales. Agreement between time points was assessed with the McNemar test, and the relationship between understanding and treatment was assessed only for the subset not on treatment at baseline. Results: Of 1000 patients enrolled in SATELLITE, 506 had 6-month survey data (data collection is continuing). Among these, the median age was 69.0 years (IQR 63.0 - 76.0) and 93.7% (474 of 506) were white. There was evidence of improvement in the self-reported understanding of warfarin and NOACs from baseline to 6 months, but not for rhythm control, ablation or cardioversion. The proportion reporting high understanding improved significantly for warfarin (p<.0001) and NOACs (p<.0001) from 47% (223 of 474) and 51% (245 of 481) at baseline to 60% (284 of 474) and 69% (332 of 481) at 6 months respectively (Figure 1). Patients with high understanding of the benefits of ablation (p=0.0005) and options for ablation (p=0.0093) at baseline were more likely to have this therapy at the 6 month follow up (N=590), but improved understanding was not associated with increased use of warfarin/NOACs (N=83) or rhythm control (N=444). Conclusions: Patients with new-onset AF had improved self-reported understanding of some treatment options over the first 6-months from diagnosis; however, factors other than patient understanding may influence AF treatments received at 6 months. Patient understanding of AF treatments remains suboptimal at 6 months, and our results suggest a need for ongoing patient education.
Gas Exchange Estimate of Pulmonary Capacitance is Similar in Cystic Fibrosis Patients and Healthy Humans When Matched for Stroke Volume
Kasak, A., Wheatley, Courtney M. , Snyder, Eric M., Baker, Sarah , Kasak, Alexander

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 29 | Issue: S1 | Pages: No page available

10.1096/fasebj.29.1_supplement.679.2 Get It

Pulmonary artery capacitance (Pa CAP ) is the ability of the pulmonary artery to accept a volume of blood at a given pressure. Measured invasively with heart catheterization; Pa CAP can be estimated non‐invasively through the measurement of end‐tidal CO 2 (P ETCO2 ) and stroke volume (SV), known as gas‐exchange capacitance (GX CAP ). We have shown that GX CAP is decreased at rest as well as during peak exercise in patients with cystic fibrosis (CF), when compared to healthy subjects. To determine whether GX CAP is different in CF and controls at a workload that matches for SV. 9 CF patients (age=22±3yrs, BMI=23±1kg/m 2 , VO 2 =19±1mL/kg/min, FEV 1 =81±8%pred.) and 13 healthy subjects (age=28±3yrs, BMI=25±1kg/m 2 , VO 2 =23±2L/min, FEV 1 =93±3%pred.) were studied. Exercise testing was performed on a cycle ergometer. P ETCO2 was assessed using a metabolic cart, SV was calculated from heart rate and cardiac output (Q) using the acetylene rebreathe technique and GX CAP was calculated as the product of P ETCO2 and SV. When matched for workload which sought to match SV, there was a significant difference in CF and healthy subjects in workload (Watts=72±6 vs. 90±4W), but no difference in percent of max watts (%MaxW=63±4 vs. 66±5W), Q (11±1 vs. 13±1L/min), or SV (89±4 vs. 90±4ml/beat). When matched, the previous difference in GX CAP in healthy and CF was abolished (GX CAP =32±2 vs. 32±2mL/BEAT • min). P ETCO2 was similar between CF and healthy subjects (P ETCO2 36±1 and 35±1mmHg). When matched for SV, GX CAP was statistically similar in CF. In relatively healthy CF there is no evidence of pulmonary vasculature dysfunction. NIH RO1 HL108962‐02
Relationship of VO 2 with Cardiac Hemodynamics Improves During Exercise in Cystic Fibrosis Patients
Wheatley, Courtney M. , Baker, Sarah , Snyder, Eric M., Iterson, Erik H. Van

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 29 | Issue: S1 | Pages: No page available

10.1096/fasebj.29.1_supplement.675.9 Get It

Background Although lower vs. healthy individuals, diffusion capacity of lungs for carbon monoxide (DL CO ) and nitric oxide (DL NO ) (may influence oxygen uptake, VO 2 ) are higher during exercise vs. rest in cystic fibrosis patients (CF). Thus, because the Fick equation suggests cardiac output (Q) increases linearly with VO 2 , we sought to study relationships between VO 2 with cardiac function from rest to peak exercise as increases in Q, DL CO and DL NO occur during exercise in CF. Methods 50 individuals participated (ages 22 ± 2 vs. 27 ± 2, BSA = 1.7 ± 0.1 vs. 1.8 ± 0.0 m 2 , VO 2peak = 24 ± 2 vs. 35 ± 2 ml/kg/min, CF (n = 19) vs. controls (CTL, n = 31), mean ± SEM, p<0.05 for all). Acetylene rebreathe was used to assess Q and calculate stroke volume (SV), and standard gas‐exchange was used to assess VO 2 (mL/kg/min). Cardiac power (CP, Q i × MAP) and stroke work (SW, SV i × MAP) were calculated. Q and SV were indexed to BSA (Q i and SV i ). Results Linear regression (R 2 ) between VO 2 with SV i , Q i , CP, and SW at rest were similarly negligible for CF vs. CTL (p=ns). At 50 % VO 2peak , R 2 between VO 2 with SV i (0.25 and 0.43, p<0.05), Q i (0.37 and 0.41, p<0.05), CP (0.18, p=ns and 0.25, p<0.05), and SW (0.12 and 0.30, p=ns) improved for CF and CTL, respectively. At VO 2peak , stronger R 2 between VO 2 with SV i (0.41, p<0.05), Q i (0.47, p<0.05), CP (0.24, p<0.05), and SW (0.19, p=ns) occurred in CF; but, R 2 weakened in CTL (0.28, p<0.05; 0.33, p<0.05; 0.07, p=ns; 0.02, p=ns, respectively). Conclusions From rest to VO 2peak the relationship between VO 2 with cardiac function improves in CF patients. Participation in exercise may benefit relationships between gas‐transfer with cardiac hemodynamics in CF patients.